171 related articles for article (PubMed ID: 21830868)
1. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
van Schaik RH; Kok M; Sweep FC; van Vliet M; van Fessem M; Meijer-van Gelder ME; Seynaeve C; Lindemans J; Wesseling J; Van 't Veer LJ; Span PN; van Laarhoven H; Sleijfer S; Foekens JA; Linn SC; Berns EM
Pharmacogenomics; 2011 Aug; 12(8):1137-46. PubMed ID: 21830868
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.
Ruiter R; Bijl MJ; van Schaik RH; Berns EM; Hofman A; Coebergh JW; van Noord C; Visser LE; Stricker BH
Pharmacogenomics; 2010 Oct; 11(10):1367-75. PubMed ID: 21047200
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
Okishiro M; Taguchi T; Jin Kim S; Shimazu K; Tamaki Y; Noguchi S
Cancer; 2009 Mar; 115(5):952-61. PubMed ID: 19156902
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.
Damkier P; Kjærsgaard A; Barker KA; Cronin-Fenton D; Crawford A; Hellberg Y; Janssen EAM; Langefeld C; Ahern TP; Lash TL
Sci Rep; 2017 Aug; 7(1):7727. PubMed ID: 28798474
[TBL] [Abstract][Full Text] [Related]
6. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
Thota K; Prasad K; Basaveswara Rao MV
Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Hauptmann M; van Schaik RH; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res Treat; 2013 Jun; 139(3):649-55. PubMed ID: 23736997
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
Serrano D; Lazzeroni M; Zambon CF; Macis D; Maisonneuve P; Johansson H; Guerrieri-Gonzaga A; Plebani M; Basso D; Gjerde J; Mellgren G; Rotmensz N; Decensi A; Bonanni B
Pharmacogenomics J; 2011 Apr; 11(2):100-7. PubMed ID: 20309015
[TBL] [Abstract][Full Text] [Related]
9. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.
Sim S; Lövrot J; Lindh JD; Bergh J; Xie H
Pharmacogenomics; 2018 Aug; 19(13):1027-1037. PubMed ID: 30022682
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
Goetz M; Suman V
Cancer; 2010 Feb; 116(4):1007; author reply 1008. PubMed ID: 20041480
[No Abstract] [Full Text] [Related]
12. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
Karle J; Bolbrinker J; Vogl S; Kreutz R; Denkert C; Eucker J; Wischnewsky M; Possinger K; Regierer AC
Breast Cancer Res Treat; 2013 Jun; 139(2):553-60. PubMed ID: 23686417
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
Kiyotani K; Mushiroda T; Sasa M; Bando Y; Sumitomo I; Hosono N; Kubo M; Nakamura Y; Zembutsu H
Cancer Sci; 2008 May; 99(5):995-9. PubMed ID: 18294285
[TBL] [Abstract][Full Text] [Related]
15. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.
Moyer AM; Suman VJ; Weinshilboum RM; Avula R; Black JL; Safgren SL; Kuffel MJ; Ames MM; Ingle JN; Goetz MP
Pharmacogenomics; 2011 Nov; 12(11):1535-43. PubMed ID: 21961651
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
[TBL] [Abstract][Full Text] [Related]
17. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
[TBL] [Abstract][Full Text] [Related]
18. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
Gjerde J; Geisler J; Lundgren S; Ekse D; Varhaug JE; Mellgren G; Steen VM; Lien EA
BMC Cancer; 2010 Jun; 10():313. PubMed ID: 20565970
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]